Cargando…

MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma

BACKGROUND: Cell-division cycle 20 (CDC20) is overexpressed in a variety of tumor cells and is negatively regulated by wild-type p53 (wtp53). Our previous study uncovered that CDC20 was upregulated and associated with poor outcome in diffuse large B-cell lymphoma (DLBCL) based on bioinformatics anal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Chengtao, Li, Mengzhen, Feng, Yanfen, Sun, Feifei, Zhang, Li, Xu, Yanjie, Lu, Suying, Zhu, Jia, Huang, Junting, Wang, Juan, Hu, Yang, Zhang, Yizhuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575066/ https://www.ncbi.nlm.nih.gov/pubmed/33116627 http://dx.doi.org/10.2147/OTT.S253758

Ejemplares similares

IDO1 plays a tumor-promoting role via MDM2-mediated suppression of the p53 pathway in diffuse large B-cell lymphoma
por: Sun, Chengtao, et al.
Publicado: (2022)

ISL1 promoted tumorigenesis and EMT via Aurora kinase A-induced activation of PI3K/AKT signaling pathway in neuroblastoma
por: Li, Mengzhen, et al.
Publicado: (2021)

Outcomes of Burkitt lymphoma with bone marrow involvement or Burkitt leukemia in Chinese children
por: Zhu, Jia, et al.
Publicado: (2021)

An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era
por: Sun, Feifei, et al.
Publicado: (2018)

Influence of Methylenetetrahydrofolate Reductase C677T and A1298C Polymorphism on High-Dose Methotrexate-Related Toxicities in Pediatric Non-Hodgkin Lymphoma Patients
por: Lu, Suying, et al.
Publicado: (2021)

Bioinformatics Analysis and Validation Identify CDK1 and MAD2L1 as Prognostic Markers of Rhabdomyosarcoma
por: Lu, Suying, et al.
Publicado: (2020)

Gene expression profiles analysis identifies a novel two-gene signature to predict overall survival in diffuse large B-cell lymphoma
por: Sun, Chengtao, et al.
Publicado: (2019)

CHIC Risk Stratification System for Predicting the Survival of Children With Hepatoblastoma: Data From Children With Hepatoblastoma in China
por: Huang, Junting, et al.
Publicado: (2020)

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
por: Zhu, Jia, et al.
Publicado: (2022)

p53 directly downregulates the expression of CDC20 to exert anti-tumor activity in mantle cell lymphoma
por: Chen, Yingtong, et al.
Publicado: (2023)

Multimodal Treatment of Children With Sacrococcygeal Yolk Sac Tumor: Retrospective Analysis of Clinicopathology Characteristics and Relapse-free Survival
por: Zhu, Jia, et al.
Publicado: (2021)

Long‐term follow‐up results of pediatric and adolescent patients with localized Ewing sarcoma treated based on stratified modalities
por: Zeng, Chenggong, et al.
Publicado: (2023)

Investigation of chemoresistance to first-line chemotherapy and its possible association with autophagy in high-risk neuroblastoma
por: Chen, Tingting, et al.
Publicado: (2022)

Histological transformation from gastric mucosa-associated lymphoid tissue lymphoma to gastric diffuse large B-cell lymphoma
por: Li, Xiaowu, et al.
Publicado: (2017)

Regulation of p53: a collaboration between Mdm2 and MdmX
por: Pei, Dongsheng, et al.
Publicado: (2012)

Ribosomal Proteins RPL37, RPS15 and RPS20 Regulate the Mdm2-p53-MdmX Network
por: Daftuar, Lilyn, et al.
Publicado: (2013)

The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study
por: Sun, Feifei, et al.
Publicado: (2020)

Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer
por: Que, Yi, et al.
Publicado: (2021)

A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma
por: Luo, Qiuyun, et al.
Publicado: (2020)

Identification of prognostic immune-related genes in rhabdoid tumor of kidney based on TARGET database analysis
por: Chen, Huimou, et al.
Publicado: (2021)

Oral vinorelbine and continuous low doses of cyclophosphamide in pediatric rhabdomyosarcoma: a real-world study
por: Lan, Yingxia, et al.
Publicado: (2023)

The MDM2-p53 pathway revisited
por: Nag, Subhasree, et al.
Publicado: (2013)

Influence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen
por: Zhu, Xiaoqin, et al.
Publicado: (2021)

Targeting RING domains of Mdm2–MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells
por: Wu, W, et al.
Publicado: (2015)

Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study
por: Que, Yi, et al.
Publicado: (2023)

The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors
por: Lu, Suying, et al.
Publicado: (2022)

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
por: Hirose, Mitsuaki, et al.
Publicado: (2014)

Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction
por: Thayer, Kelly M., et al.
Publicado: (2016)

KDM5B promotes tumorigenesis of Ewing sarcoma via FBXW7/CCNE1 axis
por: Chen, Binbin, et al.
Publicado: (2022)

Regulation of kidney development by the Mdm2/Mdm4–p53 axis
por: El-Dahr, Samir, et al.
Publicado: (2017)

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
por: Mrkvová, Zuzana, et al.
Publicado: (2019)

The RP-Mdm2-p53 Pathway and Tumorigenesis
por: Miliani de Marval, Paula L., et al.
Publicado: (2011)

Heterogeneous Hydration of p53/MDM2 Complex
por: Guo, Zuojun, et al.
Publicado: (2014)

Fortifying p53 – beyond Mdm2 inhibitors
por: Sriraman, Anusha, et al.
Publicado: (2016)

CDC20 Knockdown and Acidic Microenvironment Collaboratively Promote Tumorigenesis through Inhibiting Autophagy and Apoptosis
por: Gu, Qingying, et al.
Publicado: (2020)

Structural Basis of Competitive Recognition of p53 and MDM2 by HAUSP/USP7: Implications for the Regulation of the p53–MDM2 Pathway
por: Hu, Min, et al.
Publicado: (2006)

Compound 331 selectively induces glioma cell death by upregulating miR-494 and downregulating CDC20
por: Zhang, Lei, et al.
Publicado: (2015)

Detection of P53 and Mdm2 in vitiligo
por: Wiwanitkit, Viroj
Publicado: (2013)

Evolution of the p53-MDM2 pathway
por: Åberg, Emma, et al.
Publicado: (2017)

Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule
por: Grinkevich, Vera V., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sfplgr8uql86l6k09vj8633fec